Matthew Young

Dr. Matthew Young is a Medical Oncologist at the Dr. H. Bliss Murphy Cancer Centre in St. John’s, Newfoundland. He received his MD from Memorial University of Newfoundland in 2017 and completed a residency in Internal Medicine at Memorial in 2020. He completed his Medical Oncology training at McGill University in 2022. He then completed a two-year clinical research fellowship in clinical trials and genitourinary cancers at Barts Cancer Institute in London, UK.

Dr. Young is involved in the treatment of genitourinary, skin and breast cancers. He has been an investigator on several phase II and III clinical trials. His research interests are predominantly in drug development for bladder and kidney cancers and biomarkers. He has successfully published manuscripts in leading journals and has contributed to international guidelines for kidney cancer.

Dr. Young is a Clinical Assistant Professor within the Discipline of Oncology at the Faculty of Medicine, Memorial University of Newfoundland.

SELECTED PUBLICATIONS

Young, M., Jackson-Spence, F., Beltran, L., Day, E., Suarez,C., Bex, A., ... & Szabados, B. (2024). Renal cell carcinoma. The Lancet, 404(10451), 476-491.

Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V.,Kanesvaran, R., ... Young, M. & Gillessen, S. (2024). Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology

Young, M., Tapia, J. C., Szabados, B., Jovaisaite, A., Jackson-Spence, F., Nally, E., & Powles, T. (2024). NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 22(3), 102072.

Nally, E., Young, M., Chauhan, V., Wells, C., Szabados, B., Powles, T., & Jackson-Spence, F. (2024). Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge. Cancer Management and Research,467-475.

Jackson-Spence, F., Ackerman, C., Jones, R., Toms, C., Jovaisaite, A., Young, M., ... & Szabados, B. (2024,November). Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel. Urologic Oncology: Seminars and Original Investigations (Vol. 42, No. 11, pp. 372-e1). Elsevier.

Young, M. (2024). The Future of Front-line Metastatic Bladder Cancer is Platinum-free. European Urology Focus,10(2), 215-216.

Jackson-Spence, F., Young, M., Jovaisaite, A., Szabados, B.,& Powles, T. (2024). Adjuvant Therapy in Renal Cell Cancer. Kidney Cancer, 8(1), 17-22.

Jackson-Spence, F., Young, M., Sweeney, C., & Powles, T. (2023). Top advances of the year: Genitourinary cancer. Cancer, 129(17), 2603–2609.https://doi.org/10.1002/cncr.34907

Shastry, M., Gupta, A., Chandarlapaty, S., Young, M., Powles, T., & Hamilton, E. (2023). Rise of Antibody-Drug Conjugates: The Present and Future. American Society of Clinical Oncology Educational Book, 43, e390094.

AWARDS

• ASCO GU Merit Award (2023)
• UK Rising Star in Renal Cell Carcinoma (2023)